The negative impacts of stress on antiretroviral therapy (ART) adherence and the many stressors faced by people returning from incarceration support the need for stress reduction interventions for this population. We hypothesized that 37 returning citizens living with HIV and substance use problems randomized to a 12-session weekly yoga intervention would experience improved ART adherence, lower viral loads, and lower heart rate and blood pressure as compared to 36 people randomized to treatment as usual (TAU). We found that ART adherence increased for yoga participants and decreased for TAU participants. There were no significant changes for viral load, heart rate, or blood pressure. The lack of statistically significant effects may be due to a small sample size and enrollment of people largely in HIV treatment. Studies with larger sample sizes and participants exhibiting low ART adherence are warranted to better understand yoga’s impact.
AgarwalR. P., KumarA., LewisJ. E. (2015). A pilot feasibility and acceptability study of yoga/meditation on the quality of life and markers of stress in persons living with HIV who also use crack cocaine. Journal of Alternative and Complementary Medicine, 21(3), 152–158. http://doi.org/10.1089/acm.2014.0112
2.
AmmassariA., TrottaM. P., MurriR., CastelliF., NarcisoP., NotoP., VecchietJ, D’Arminio MonforteA., WuA. W., AntinoriA., & AdICoNA Study Group. (2002). Correlates and predictors of adherence to highly active antiretroviral therapy: Overview of published literature. Journal of Acquired Immune Deficiency Syndromes, 31, S123–S127.
3.
ArnstenJ. H., DemasP. A., GrantR. W., GourevitchM. N., FarzadeganH., HowardA. A., SchoenbaumE. E. (2002). Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. Journal of General Internal Medicine, 17(5), 377–381.
4.
BaillargeonJ., GiordanoT. P., RichJ. D., WuZ. H., WellsK., PollockB. H., PaarD. P. (2009). Accessing antiretroviral therapy following release from prison. Journal of the American Medical Association, 301, 848–857. http://doi.org/10.1001/jama.2009.202
5.
BaraiN., MonroeA., LeskoC., LauB., HuttonH., YangC., AlvanzoA., McCaulM. E., ChanderG. (2017). The association between changes in alcohol use and changes in antiretroviral therapy adherence and viral suppression among women living with HIV. AIDS and Behavior, 21(7), 1836–1845. http://doi.org/10.1007/s10461-016-1580-x
6.
BeckwithC. G., ZallerN. D., FuJ. J., MontagueB. T., RichJ. D. (2010). Opportunities to diagnose, treat, and prevent HIV in the criminal justice system. Journal of Acquired Immune Deficiency Syndromes, 55(Suppl 1), S49–S55. http://doi.org/10.1097/QAI.0b013e3181f9c0f7
7.
BennettD. A. (2001). How can I deal with missing data in my study?. Australian and New Zealand Journal of Public Health, 25, 464–469.
8.
BonadiesV. (2004). A yoga therapy program for AIDS-related pain and anxiety: Implications for therapeutic recreation. Therapeutic Recreation Journal, 38(2), 148–166.
9.
CadeW. T., ReedsD. N., MondyK. E., OvertonE. T., GrassinoJ., TuckerS., BoppC., LacinyE., HubertS., Lassa-ClaxtonS., YarasheskiK. E. (2010). Yoga lifestyle intervention reduces blood pressure in HIV-infected adults with cardiovascular disease risk factors. HIV Medicine, 11, 379–388. http://doi.org/10.1111/j.1468-1293.2009.00801.x
10.
CarlsonL. E., SpecaM., FarisP., PatelK. D. (2007). One year pre–post intervention follow-up of psychological, immune, endocrine and blood pressure outcomes of mindfulness-based stress reduction (MBSR) in breast and prostate cancer outpatients. Brain, Behavior, and Immunity, 21, 1038–1049. http://doi.org/10.1016/j.bbi.2007.04.002
11.
CastillaJ., Del RomeroJ., HernandoV., MarincovichB., GarciaS., RodreiguezC. (2005). Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. Journal of Acquired Immune Deficiency Syndromes, 40, 96–101.
Clements-NolleK., MarxR., PendoM., LoughranE., EstesM., KatzM. (2008). Highly active antiretroviral therapy use and HIV transmission risk behaviors among individuals who are HIV infected and were recently released from jail. American Journal of Public Health, 98, 661–666. http://doi.org/10.2105/AJPH.2007.112656
14.
DehovitzJ. A., KovacsA., FeldmanJ. G., AnastosK., YoungM., CohenM., GangeS. J., MelnickS., GreenblattR. M. (2000). The relationship between virus load response to highly active antiretroviral therapy and change in CD4 cell counts: A report from the Women’s Interagency HIV Study. Journal of Infectious Diseases, 182, 1527–1530.
15.
FrenchT., TesorieroJ., AginsB. (2011). Changes in stress, substance use and medication beliefs are associated with changes in adherence to HIV antiretroviral therapy. AIDS and Behavior, 15(7), 1416–1428. http://doi.org/10.1007/s10461-010-9762-4
16.
FriedmannP. D., RoseJ. S., SwiftR., StoutR. L., MillmanR. P., SteinM. D. (2008). Trazodone for sleep disturbance after alcohol detoxification: A double-blind, placebo-controlled trial. Alcoholism: Clinical and Experimental Research, 32, 1652–1660. http://doi.org/10.1111/j.1530-0277.2008.00742.x
17.
GonzalezA., MimiagaM. J., IsraelJ., BedoyaC. A., SafrenS. A. (2013). Substance use predictors of poor medication adherence: The role of substance use coping among HIV-infected patients in opioid dependence treatment. AIDS and Behavior, 17, 168–173. http://doi.org/10.1007/s10461-012-0319-6
18.
GrossR., YipB., ReV. L.III, WoodE., AlexanderC. S., HarriganP. R., BangsbergD. R., MontanerJ. S., HoggR. S. (2006). A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. Journal of Infectious Diseases, 194, 1108–1114.
19.
GrossbergR., GrossR. (2007). Use of pharmacy refill data as a measure of antiretroviral adherence. Current HIV/AIDS Reports, 4, 187–191.
20.
GrossbergR., ZhangY., GrossR. (2004). A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV. Journal of Clinical Epidemiology, 57, 1107–1110. http://doi.org/10.1016/j.jclinepi.2004.04.002
IrohP. A., MayoH., NijhawanA. E. (2015). The HIV care cascade before, during, and after incarceration: A systematic review and data synthesis. American Journal of Public Health, 105(7), e5–e16. http://doi.org/10.2105/AJPH.2015.302635
23.
LesermanJ., IronsonG., O’CleirighC., FordianiJ. M., BalbinE. (2008). Stressful life events and adherence in HIV. AIDS Patient Care and STDs, 22, 403–411. http://doi.org/10.1089/apc.2007.0175
24.
LiA. W., GoldsmithC.-A. W. (2012). The effects of yoga on anxiety and stress. Alternative Medicine Review, 17(1), 21–35.
25.
MacyR. J., JonesE., GrahamL. M., RoachL. (2018). Yoga for trauma and related mental health problems: A meta-review with clinical and service recommendations. Trauma, Violence and Abuse, 19(1), 35–57. http://doi.org/10.1177/1524838015620834
26.
MaruschakL. M. (2012). HIV in prisons, 2001–2010 (NCJ 238877). Bureau of Justice Statistics.
27.
MeyerJ. P., CepedaJ., WuJ., TrestmanR. L., AlticeF. L., SpringerS. A. (2014). Optimization of human immunodeficiency virus treatment during incarceration: Viral suppression at the prison gate. JAMA Internal Medicine, 174, 721–729. http://doi.org/10.1001/jamainternmed.2014.601
28.
PatersonD. L., SwindellsS., MohrJ., BresterM., VergisE. N., SquierC., WagenerM. M., SinghN. (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine, 133(1), 21–30. http://doi.org/10.7326/0003-4819-133-1-200007040-00004
29.
PorcoT. C., MartinJ. N., Page-ShaferK. A., ChengA., CharleboisE., GrantR. M., OsmondD. H. (2004). Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS, 18(1), 81–88.
30.
SethiA. K., CelentanoD. D., GangeS. J., MooreR. D., GallantJ. E. (2003). Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clinical Infectious Diseases, 37, 1112–1118. http://doi.org/10.1086/378301
31.
SinhaR. (2001). How does stress increase risk of drug abuse and relapse?. Psychopharmacology, 158, 343–359.
32.
SinhaR. (2008). Chronic stress, drug use, and vulnerability to addiction. Annals of the New York Academy of Sciences, 1141, 105–130. http://doi.org/10.1196/annals.1441.030
33.
SteinerJ. F., KoepsellT. D., FihnS. D., InuiT. S. (1988). A general method of compliance assessment using centralized pharmacy records: Description and validation. Medical Care, 26, 814–823.
34.
StephensonB. L., WohlD. A., GolinC. E., TienH.-C., StewartP., KaplanA. H. (2005). Effect of release from prison and re-incarceration on the viral loads of HIV-infected individuals. Public Health Reports, 120(1), 84–88. http://doi.org/10.1177/003335490512000114
35.
SwanH. (2015). Different patterns of drug use and barriers to continuous HIV care post-incarceration. Journal of Drug Issues, 45(1), 38–52. http://doi.org/10.1177/0022042614542512
36.
WesternB., BragaA. A., DavisJ., SiroisC. (2015). Stress and hardship after prison. American Journal of Sociology, 120, 1512–1547.
37.
WimberlyA. S., EngstromM., LaydeM., McKayJ. R. (2018). A randomized trial of yoga for stress and substance use among people living with HIV in reentry. Journal of Substance Abuse Treatment, 94, 97–104. http://doi.org/10.1016/j.jsat.2018.08.001
